Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Featured News
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
State Council Issues Major Pharma Industry Reform Policy
A major reform policy covering full process of the pharmaceutical industry, Certain Opinions for Further Reform and Improvement of Pharmaceutical Manufacturing, Distribut... (2/9/2017)
   
China Works to Reduce Massive Backlog of Clinical Trial and Marketing Applications (2/15/2017)
Can Technology Really Solve China's Healthcare Crisis? (2/14/2017)
China's Tech Tycoons' Healthcare Dreams Aren't Coming True (2/13/2017)
Five Elements to Consider When Choosing the Next Emerging Market to Enter (2/13/2017)
China Will Continue To Rise As A Key Base for Global Pharmaceutical Manufacturing (2/8/2017)
PwC: Chinese Hospital M&A Review and Outlook H1/2016 (2/7/2017)
Mobile Medical Healthcare Trends in China (2/6/2017)
Tough and Turbulent Time Ahead in the Coming Year of Trump Rooster - 2016 Annual Review & 2017 Outlook (2/2/2017)
Review of Chinese Pharma Deals, R&D and Regulatory Developments in 2016 (2/1/2017)
2016 Compliance Enforcement in the Pharmaceutical Industry (1/26/2017)
Are Reforms Focused on Pharma Kickbacks in China, the Last Straw to Push Doctors to Leave? (1/24/2017)
RDPAC Releases New Report on Meeting the Cancer Challenges in China (1/23/2017)
The Outlook for China in the Global Pharmaceutical Market (1/19/2017) (free)
The Diabetes Epidemic in China: An Integrated Review of National Surveys (1/17/2017)
Inefficient Innovation in China (1/16/2017)
Recent Executive Moves  (2/16/2017)
CFDA Releases Three Technical Guidelines...  (2/16/2017)
India Pressures CFDA to Act and Restore ...  (2/16/2017)
Lee's Pharma Licenses Greater China Righ...  (2/15/2017)
GBI: Asia-Pacific Influenza Vaccines Mar...  (2/15/2017)
Chinese Animal Vaccine Market to Reach C...  (2/15/2017)
CSL Reports Strong China Business, Helpe...  (2/15/2017)
PhRMA Urges USTR to Protect US Innovatio...  (2/14/2017)
CFDA Issues Incentive Measures for Food ...  (2/14/2017)
Upcoming Event: Pharma China Annual Foru...  (2/14/2017) (free)
State Council Issues Medium and Long Ter...  (2/14/2017)
China Cracks Down on First Pharma Antimo...  (2/14/2017)
Chinese Biotech Cstone Raises $150 Milli...  (2/13/2017)
Inovio, ApolloBio Enter Licensing Deal f...  (2/13/2017) (free)
MOHRSS Expected to Issue Policy for Unif...  (2/13/2017)
PhRMA Urges USTR to Protect US Innovation Abroad
Trump Wants Big Pharma Cut Outsourcing and Prices, Promi...
Mergermarket: Global Pharma and Biotech M&A Feels th...
Trump Challenges Pharma Outsourcing, Unnerving Drug Make...
New Pharma Rankings On Global Access To Medicine Release...
GBI: Asia-Pacific Influenza Vaccines Market to Surpass $1.7B by...
Chinese Animal Vaccine Market to Reach CNY 41 Bln by 2020
Data Snapshot - Hospital Consumption COPD Drugs in Shanghai
Deutsche Bank Expects Substantial mAb Market Growth in China
Nicholas Hall: Chinese OTC Drug Sales Growth Slows
Lee's Pharma Licenses Greater China Rights of Episil from So...
CSL Reports Strong China Business, Helped by Rising Demand f...
Chinese Biotech Cstone Raises $150 Million in New Financing
Inovio, ApolloBio Enter Licensing Deal for Greater China Rig...
EU: Chinese Biopharma R&D Investment Growth Highest Glob...
CFDA Releases Three Technical Guidelines for Generic Dru...
CFDA Issues Incentive Measures for Food and Drug Compani...
State Council Issues New Policy for Vaccine Distribution...
CFDA Seeks Public Comments on Health Food Filing Rules
CFDA Issues Announcement over General Considerations for...
China Cracks Down on First Pharma Antimonopoly Case in 2017
China Issues Five Year Plan for Intellectual Property Develo...
USTR Releases 2016 Report on China's WTO Compliance Highligh...
SAIC Fines Southwest No.2 Pharma for API Sales Monopoly
NDRC Fines MedTronic CNY 118.5M for Alleged Price-fixing
India Pressures CFDA to Act and Restore Supply of Rare D...
U.S. FDA Warns Suzhou PharmTech, Putting It on Import Al...
New Report: Prospects of Chinese API Industry Up in the ...
U.S. FDA Warns Chinese Heparin Producer Dongying Tiandon...
India Puts Chinese APIs on Radar over Quality Concerns
TaiGen Reports Positive Phase II Results for Its HCV Dru...
Sirnaomics Initiates a Clinical Phase IIa Study of Its s...
FirboGen Posts Positive Chinese Phase III Data for AZ-Pa...
WuXi MedImmune Secures CFDA’s Clinical Approval for Pha...
Chi-Med Initiates a Phase II Study of Sulfatinib in Seco...
State Council Issues Medium and Long Term Plan for Preve...
MOHRSS Expected to Issue Policy for Uniform BMI Payment ...
Baidu Withdraws from Mobile Healthcare to Focus on AI-en...
NHFPC Issues New Policy for Trial of Medical Consortiums...
China to Issue A Major Reform Policy Covering Full Proce...
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Former CFDA Official Handed Ten Year Imprisonment for Corr...
Upcoming Event: Pharma China Annual Forum 2017 in Shangh...
Upcoming Event: Cancer Science 2017
Upcoming Event: BioPharma Asia 2017
Upcoming Event: DCAT Week' 17
Upcoming Event: Generic International Summit Asia 2017
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON Officially Publishes Chi...
  WiCON and PharmaGuys Launch Ph...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Its...
  WiCON Publishes China Pharmace...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links